Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11719525 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Stocco CO, Lau LF, Gibori G (2002) A calcium/calmodulin-dependent activation of ERK1/2 mediates JunD phosphorylation and induction of nur77 and 20alpha-hsd genes by prostaglandin F2alpha in ovarian cells. J Biol Chem 277, 3293-302 11719525
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T203-p - ERK1 (rat)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'granulosa, luteal'
 Cellular systems studied:  primary cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PGE2a increase
W-7 PGE2a inhibit treatment-induced increase
BAPTA-AM PGE2a inhibit treatment-induced increase

Y205-p - ERK1 (rat)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'granulosa, luteal'
 Cellular systems studied:  primary cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PGE2a increase
W-7 PGE2a inhibit treatment-induced increase
BAPTA-AM PGE2a inhibit treatment-induced increase

T183-p - ERK2 (rat)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'granulosa, luteal'
 Cellular systems studied:  primary cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PGE2a increase
W-7 PGE2a inhibit treatment-induced increase
BAPTA-AM PGE2a inhibit treatment-induced increase

Y185-p - ERK2 (rat)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'granulosa, luteal'
 Cellular systems studied:  primary cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PGE2a increase
W-7 PGE2a inhibit treatment-induced increase
BAPTA-AM PGE2a inhibit treatment-induced increase

S100-p - JunD (rat)
Orthologous residues
JunD (human): S100‑p, JunD (mouse): S100‑p, JunD (rat): S100‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'granulosa, luteal'
 Cellular systems studied:  primary cells
 Species studied:  rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (rat) pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme
KINASE ERK2 (rat) pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PGE2a increase
BAPTA-AM PGE2a inhibit treatment-induced increase
W-7 PGE2a inhibit treatment-induced increase
PD98059 PGE2a inhibit treatment-induced increase
SB203580 PGE2a augment treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.